30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Mereo BioPharma Group PLC (MREO)

Track

The most recent insider trading activity occurred on September 13, 2024, with multiple executives, including the CEO and CFO, reporting significant sell transactions. These sales represent a notable pattern of divestment by key personnel within the company.
Stock chart
Ticker: MREO Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Sermon Charles
General Counsel
1 sale — total 88,413 USD
Sale 13 Sep 2024
Value US$3,254,944.55 | Price 441.53 | Shares 8,957
Sale 13 Sep 2024
Value US$3,612,096.49 | Price 379.96 | Shares 6,587
Sale 13 Sep 2024
Value US$46,165.08 | Price 4.22 | Shares 10,937
Sale 13 Sep 2024
Value US$253,454.17 | Price 4.22 | Shares 60,046
Sale 13 Sep 2024
Value US$354,597.77 | Price 4.22 | Shares 84,008
Sale 13 Sep 2024
Value US$68,819.18 | Price 4.22 | Shares 16,304
Sale 12 Sep 2024
Value US$44,637.55 | Price 4.47 | Shares 9,980
Proposed sale 12 Sep 2024
Value US$144,115.16 | Price 4.66 | Shares 30,926
Sale 12 Sep 2024
Value US$40,826.81 | Price 4.47 | Shares 9,128
Proposed sale 12 Sep 2024
Value US$131,812.76 | Price 4.66 | Shares 28,286
Sale 12 Sep 2024
Value US$23,311.71 | Price 4.47 | Shares 5,212
Proposed sale 12 Sep 2024
Value US$75,254.34 | Price 4.66 | Shares 16,149
Sale 12 Sep 2024
Value US$127,968.42 | Price 4.47 | Shares 28,611
Proposed sale 12 Sep 2024
Value US$413,141.62 | Price 4.66 | Shares 88,657
Sale 12 Sep 2024
Value US$179,037.71 | Price 4.47 | Shares 40,029
Sale 12 Sep 2024
Value US$34,748.41 | Price 4.47 | Shares 7,769
Proposed sale 12 Sep 2024
Value US$690,192.60 | Price 4.66 | Shares 148,110
Sale 22 Aug 2024
Value US$466,209.87 | Price 4.43 | Shares 105,244
Proposed sale 22 Aug 2024
Value US$466,209.87 | Price 4.43 | Shares 105,244
Sale 26 Jun 2024
Value US$109,216.93 | Price 3.39 | Shares 32,187
Sale 26 Jun 2024
Value US$57,032.91 | Price 3.39 | Shares 16,808
Sale 26 Jun 2024
Value US$77,935.02 | Price 3.39 | Shares 22,968
Sale 26 Jun 2024
Value US$99,892.41 | Price 3.39 | Shares 29,439
Sale 26 Jun 2024
Value US$313,100.74 | Price 3.39 | Shares 92,273
Sale 25 Jun 2024
Value US$52,460.77 | Price 3.69 | Shares 14,202
Proposed sale 25 Jun 2024
Value US$203,091.44 | Price 3.98 | Shares 51,028
Sale 25 Jun 2024
Value US$27,393.96 | Price 3.69 | Shares 7,416
Proposed sale 25 Jun 2024
Value US$106,055.06 | Price 3.98 | Shares 26,647
Sale 25 Jun 2024
Value US$37,433.98 | Price 3.69 | Shares 10,134
Sale 25 Jun 2024
Value US$47,983.76 | Price 3.69 | Shares 12,990
Proposed sale 25 Jun 2024
Value US$185,754.56 | Price 3.98 | Shares 46,672
Sale 25 Jun 2024
Value US$150,386.06 | Price 3.69 | Shares 40,712
Proposed sale 25 Jun 2024
Value US$582,210.32 | Price 3.98 | Shares 146,284
Proposed sale 25 Jun 2024
Value US$131,745.96 | Price 3.98 | Shares 33,102
Proposed sale 21 Jun 2024
Value US$131,745.96 | Price 3.98 | Shares 33,102
Proposed sale 21 Jun 2024
Value US$203,091.44 | Price 3.98 | Shares 51,028
Proposed sale 21 Jun 2024
Value US$185,754.56 | Price 3.98 | Shares 46,672
Proposed sale 21 Jun 2024
Value US$582,210.32 | Price 3.98 | Shares 146,284
Proposed sale 21 Jun 2024
Value US$106,055.06 | Price 3.98 | Shares 26,647
Proposed sale 22 May 2024
Value US$297,505.97 | Price 2.96 | Shares 100,432
Sale 22 May 2024
Value US$147,241.08 | Price 2.94 | Shares 50,082
Sale 22 May 2024
Value US$150,546.50 | Price 2.99 | Shares 50,350
Buy 9 Oct 2020
Value US$44,356.05 | Price 2.41 | Shares 18,405
Buy 7 Oct 2020
Value US$15,330.06 | Price 2.36 | Shares 6,496
Buy 7 Oct 2020
Value US$47,068.00 | Price 2.35 | Shares 20,029
Buy 7 Oct 2020
Value US$70,903.18 | Price 2.36 | Shares 30,044
Buy 12 Aug 2020
Value US$9,660.00 | Price 2.76 | Shares 3,500
Buy 31 Jul 2020
Value US$30,104.55 | Price 2.85 | Shares 10,563
Buy 2 Dec 2019
Value US$7,703.50 | Price 2.20 | Shares 3,500
Buy 26 Nov 2019
Value £9,891.90 | Price 0.38 | Shares 26,100
Buy 25 Nov 2019
Value £9,667.20 | Price 0.38 | Shares 25,440
Buy 22 Nov 2019
Value US$25,400.00 | Price 2.54 | Shares 10,000
Buy 19 Nov 2019
Value US$12,818.00 | Price 2.60 | Shares 4,930
Buy 19 Nov 2019
Value £4,971.29 | Price 0.39 | Shares 12,879
Buy 4 Oct 2019
Value US$1,200.85 | Price 3.29 | Shares 365
Buy 4 Oct 2019
Value £8,980.05 | Price 0.59 | Shares 15,169
Buy 30 Sep 2019
Value US$4,437.00 | Price 2.96 | Shares 1,500
Buy 25 Sep 2019
Value £1,987.80 | Price 0.60 | Shares 3,313
Buy 24 Sep 2019
Value £994.91 | Price 0.61 | Shares 1,631
Buy 20 Sep 2019
Value £456.00 | Price 0.57 | Shares 800
Buy 19 Sep 2019
Value £7,965.00 | Price 0.59 | Shares 13,500
Buy 16 Aug 2019
Value £3,210.00 | Price 0.54 | Shares 6,000
Buy 15 Aug 2019
Value US$4,969.50 | Price 3.31 | Shares 1,500
Buy 15 Aug 2019
Value £3,240.00 | Price 0.54 | Shares 6,000
Buy 15 Aug 2019
Value £3,399.93 | Price 0.54 | Shares 6,355
Buy 14 Aug 2019
Value £2,341.17 | Price 3.11 | Shares 754
Buy 13 Aug 2019
Value US$1,821.33 | Price 3.09 | Shares 590
Buy 24 Jul 2019
Value £19,950.00 | Price 0.42 | Shares 47,500
Buy 18 Jul 2019
Value £5,100.00 | Price 2.55 | Shares 2,000
Buy 18 Jul 2019
Value £3,600.00 | Price 0.45 | Shares 8,000
Buy 17 Jul 2019
Value £5,180.00 | Price 2.59 | Shares 2,000
Buy 17 Jul 2019
Value £900.00 | Price 0.45 | Shares 2,000
Buy 22 May 2019
Value US$14,709.00 | Price 4.90 | Shares 3,000
Buy 21 May 2019
Value US$3,827.76 | Price 4.92 | Shares 778
Buy 21 May 2019
Value £42,750.00 | Price 0.90 | Shares 47,500
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2024-09-16 2024-09-13 S Sale
1.8
Sermon Charles

General Counsel

Officer
8,957 -4.4%
441.53
US$3,254,945 		8,957 -4.4% 441.53 US$3,254,945
2024-09-16 2024-09-13 S Sale
1.8
Fox Christine Ann

Chief Financial Officer

Officer
6,587 +27.2%
379.96
US$3,612,096 		6,587 +27.2% 379.96 US$3,612,096
2024-09-16 2024-09-13 S Sale
1.8
Lewicki John A.

Chief Scientific Officer

Officer
97,745 +11.5%
171.74
US$832,427 		97,745 +11.5% 171.74 US$832,427
2024-09-16 2024-09-13 S Sale
1.8
Scots-Knight Denise

Chief Executive Officer

Executive Director
60,046 -6.9%
4.22
US$253,454 		60,046 -6.9% 4.22 US$253,454
2024-09-16 2024-09-13 S Sale
2.2
Hughes-Wilson Alexandra

See Remarks

Officer
84,008 -62.5%
4.22
US$354,598 		84,008 -62.5% 4.22 US$354,598
2024-09-16 2024-09-13 S Sale
2.2
Hughes-Wilson Alexandra

See Remarks

Officer
16,304 -10.8%
4.22
US$68,819 		16,304 -10.8% 4.22 US$68,819
2024-09-16 2024-09-12 S Sale
1.8
Sermon Charles

General Counsel

Officer
9,980 -4.0%
4.47
US$44,638 		9,980 -4.0% 4.47 US$44,638
2024-09-16 2024-09-12 S Sale
1.8
Fox Christine Ann

Chief Financial Officer

Officer
9,128 -7.8%
4.47
US$40,827 		9,128 -7.8% 4.47 US$40,827
2024-09-16 2024-09-12 S Sale
1.8
Lewicki John A.

Chief Scientific Officer

Officer
5,212 -5.5%
4.47
US$23,312 		5,212 -5.5% 4.47 US$23,312
2024-09-16 2024-09-12 S Sale
1.8
Scots-Knight Denise

Chief Executive Officer

Executive Director
28,611 -3.2%
4.47
US$127,968 		28,611 -3.2% 4.47 US$127,968
2024-09-16 2024-09-12 S Sale
2.2
Hughes-Wilson Alexandra

See Remarks

Officer
40,029 -21.0%
4.47
US$179,038 		40,029 -21.0% 4.47 US$179,038
2024-09-16 2024-09-12 S Sale
2.2
Hughes-Wilson Alexandra

See Remarks

Officer
7,769 -3.9%
4.47
US$34,748 		7,769 -3.9% 4.47 US$34,748
2024-09-12 2024-09-12 PrS Proposed sale
1.8
Scots-Knight Denise

Officer; Director

Executive Director
88,657
4.66
US$413,142 		88,657 4.66 US$413,142
2024-09-12 2024-09-12 PrS Proposed sale
1.8
Lewicki John A.

Officer

Officer
16,149
4.66
US$75,254 		16,149 4.66 US$75,254
2024-09-12 2024-09-12 PrS Proposed sale
2.2
Alexandra Hughes-Wilson

Officer

Officer
148,110
4.66
US$690,193 		148,110 4.66 US$690,193
2024-09-12 2024-09-12 PrS Proposed sale
1.8
Sermon Charles

Officer

Officer
30,926
4.66
US$144,115 		30,926 4.66 US$144,115
2024-09-12 2024-09-12 PrS Proposed sale
1.8
Fox Christine Ann

Officer

Officer
28,286
4.66
US$131,813 		28,286 4.66 US$131,813
2024-08-23 2024-08-22 S Sale
4.0
PAKIANATHAN DEEPIKA
Non-Executive Director
105,244 -100.0%
4.43
US$466,210 		105,244 -100.0% 4.43 US$466,210
2024-08-22 2024-08-22 PrS Proposed sale
4.0
Deepika Pakianathan

Director

Non-Executive Director
105,244
4.43
US$466,210 		105,244 4.43 US$466,210
2024-06-27 2024-06-26 S Sale
1.8
Sermon Charles

General Counsel

Officer
32,187 -14.9%
3.39
US$109,217 		32,187 -14.9% 3.39 US$109,217
2024-06-27 2024-06-26 S Sale
1.8
Lewicki John A.

Chief Scientific Officer

Officer
16,808 -25.6%
3.39
US$57,033 		16,808 -25.6% 3.39 US$57,033
2024-06-27 2024-06-26 S Sale
2.2
Hughes-Wilson Alexandra

See Remarks

Officer
22,968 -39.9%
3.39
US$77,935 		22,968 -39.9% 3.39 US$77,935
2024-06-27 2024-06-26 S Sale
1.8
Fox Christine Ann

Chief Financial Officer

Officer
29,439 -33.8%
3.39
US$99,892 		29,439 -33.8% 3.39 US$99,892
2024-06-27 2024-06-26 S Sale
1.8
Scots-Knight Denise

Chief Executive Officer

Executive Director
92,273 -11.5%
3.39
US$313,101 		92,273 -11.5% 3.39 US$313,101
2024-06-27 2024-06-25 S Sale
1.8
Sermon Charles

General Counsel

Officer
14,202 -6.2%
3.69
US$52,461 		14,202 -6.2% 3.69 US$52,461
2024-06-27 2024-06-25 S Sale
1.8
Lewicki John A.

Chief Scientific Officer

Officer
7,416 -10.2%
3.69
US$27,394 		7,416 -10.2% 3.69 US$27,394
2024-06-27 2024-06-25 S Sale
2.2
Hughes-Wilson Alexandra

See Remarks

Officer
10,134 -15.0%
3.69
US$37,434 		10,134 -15.0% 3.69 US$37,434
2024-06-27 2024-06-25 S Sale
1.8
Fox Christine Ann

Chief Financial Officer

Officer
12,990 -13.0%
3.69
US$47,984 		12,990 -13.0% 3.69 US$47,984
2024-06-27 2024-06-25 S Sale
1.8
Scots-Knight Denise

Chief Executive Officer

Executive Director
40,712 -4.8%
3.69
US$150,386 		40,712 -4.8% 3.69 US$150,386
2024-06-24 2024-06-25 PrS Proposed sale
1.8
Lewicki John A.

Officer

Officer
26,647
3.98
US$106,055 		26,647 3.98 US$106,055
2024-06-24 2024-06-25 PrS Proposed sale
1.8
Scots-Knight Denise

Officer; Director

Executive Director
146,284
3.98
US$582,210 		146,284 3.98 US$582,210
2024-06-24 2024-06-25 PrS Proposed sale
2.2
Alexandra Hughes-Wilson

Officer

Officer
33,102
3.98
US$131,746 		33,102 3.98 US$131,746
2024-06-24 2024-06-25 PrS Proposed sale
1.8
Sermon Charles

Officer

Officer
51,028
3.98
US$203,091 		51,028 3.98 US$203,091
2024-06-24 2024-06-25 PrS Proposed sale
1.8
Fox Christine Ann

Officer

Officer
46,672
3.98
US$185,755 		46,672 3.98 US$185,755
2024-06-20 2024-06-21 PrS Proposed sale
2.2
Alexandra Hughes-Wilson

Officer

Officer
33,102
3.98
US$131,746 		33,102 3.98 US$131,746
2024-06-20 2024-06-21 PrS Proposed sale
1.8
Sermon Charles

Officer

Officer
51,028
3.98
US$203,091 		51,028 3.98 US$203,091
2024-06-20 2024-06-21 PrS Proposed sale
1.8
Fox Christine Ann

Officer

Officer
46,672
3.98
US$185,755 		46,672 3.98 US$185,755
2024-06-20 2024-06-21 PrS Proposed sale
1.8
Scots-Knight Denise

Officer; Director

Executive Director
146,284
3.98
US$582,210 		146,284 3.98 US$582,210
2024-06-20 2024-06-21 PrS Proposed sale
1.8
Lewicki John A.

Officer

Officer
26,647
3.98
US$106,055 		26,647 3.98 US$106,055
2024-05-23 2024-05-22 PrS Proposed sale
2.2
Alexandra Hughes-Wilson

Officer

Officer
100,432
2.96
US$297,506 		100,432 2.96 US$297,506
2024-05-23 2024-05-22 S Sale
2.2
Hughes-Wilson Alexandra

See Remarks

Officer
50,082 -60.6%
2.94
US$147,241 		50,082 -60.6% 2.94 US$147,241
2024-05-23 2024-05-22 S Sale
2.2
Hughes-Wilson Alexandra

See Remarks

Officer
50,350 -46.2%
2.99
US$150,546 		50,350 -46.2% 2.99 US$150,546
2020-10-12 2020-10-09 B Purchase
1.8
Charles Sermon

General Counsel
18,405
2.41
US$44,356 		18,405 2.41 US$44,356
2020-10-09 2020-10-07 B Purchase John Richard

Head of Corporate Development

Officer
6,496
2.36
US$15,330 		6,496 2.36 US$15,330
2020-10-09 2020-10-07 B Purchase Brian Schwartz

Non-Executive Director

Executive Director
20,029
2.35
US$47,068 		20,029 2.35 US$47,068
2020-10-09 2020-10-07 B Purchase
1.8
Denise Scots-Knight

Chief Executive Officer

Officer
30,044
2.36
US$70,903 		30,044 2.36 US$70,903
2020-08-14 2020-08-12 B Purchase John Richard

Head of Corporate Development

Officer
3,500
2.76
US$9,660 		3,500 2.76 US$9,660
2020-08-05 2020-07-31 B Purchase
1.8
Denise Scots-Knight

Chief Executive Officer

Officer
10,563
2.85
US$30,105 		10,563 2.85 US$30,105
2019-12-03 2019-12-02 B Purchase John Richard

Head of Corporate Development

Officer
3,500
2.20
US$7,704 		3,500 2.20 US$7,704
2019-11-27 2019-11-26 B Purchase
2.4
Richard Jones

Chief Financial Officer

Officer
26,100
0.38
£9,892 		26,100 0.38 £9,892
2019-11-25 2019-11-25 B Purchase
2.4
Richard Jones

Chief Financial Officer

Officer
25,440
0.38
£9,667 		25,440 0.38 £9,667
2019-11-22 2019-11-22 B Purchase
2.1
Anders Ekblom

non-executive Director

Executive Director
10,000
2.54
US$25,400 		10,000 2.54 US$25,400
2019-11-20 2019-11-19 B Purchase
Alastair Mackinnon

Chief Medical Officer

Officer
4,930
2.60
US$12,818 		4,930 2.60 US$12,818
2019-11-20 2019-11-19 B Purchase
Alastair Mackinnon

Chief Medical Officer

Officer
12,879
0.39
£4,971 		12,879 0.39 £4,971
2019-11-22 2019-10-04 B Purchase
Alastair Mackinnon

Chief Medical Officer

Officer
365
3.29
US$1,201 		365 3.29 US$1,201
2019-11-22 2019-10-04 B Purchase
Alastair Mackinnon

Chief Medical Officer

Officer
15,169
0.59
£8,980 		15,169 0.59 £8,980
2019-10-02 2019-09-30 B Purchase John Richard

Head of Corporate Development

Officer
1,500
2.96
US$4,437 		1,500 2.96 US$4,437
2019-09-26 2019-09-25 B Purchase
Alastair MacKinnon

Chief Medical Officer

Officer
3,313
0.60
£1,988 		3,313 0.60 £1,988
2019-09-25 2019-09-24 B Purchase
Alastair MacKinnon

Chief Medical Officer

Officer
1,631
0.61
£995 		1,631 0.61 £995
2019-09-24 2019-09-20 B Purchase
Alastair MacKinnon

Chief Medical Officer

Officer
800
0.57
£456 		800 0.57 £456
2019-09-20 2019-09-19 B Purchase
1.8
Denise Scots-Knight

Chief Executive Officer

Officer
13,500
0.59
£7,965 		13,500 0.59 £7,965
2019-08-16 2019-08-16 B Purchase
1.8
Denise Scots-Knight

Chief Executive Officer

Officer
6,000
0.54
£3,210 		6,000 0.54 £3,210
2019-08-16 2019-08-15 B Purchase John Richard

Head of Corporate Development

Officer
1,500
3.31
US$4,970 		1,500 3.31 US$4,970
2019-08-16 2019-08-15 B Purchase
1.8
Denise Scots-Knight

Chief Executive Officer

Officer
6,000
0.54
£3,240 		6,000 0.54 £3,240
2019-08-16 2019-08-15 B Purchase
1.8
Charles Sermon

General Counsel
6,355
0.54
£3,400 		6,355 0.54 £3,400
2019-08-15 2019-08-14 B Purchase
1.8
Charles Sermon

General Counsel
754
3.11
£2,341 		754 3.11 £2,341
2019-08-15 2019-08-13 B Purchase
1.8
Charles Sermon

General Counsel
590
3.09
US$1,821 		590 3.09 US$1,821
2019-07-25 2019-07-24 B Purchase Peter Bains

Director

Executive Director
47,500
0.42
£19,950 		47,500 0.42 £19,950
2019-07-19 2019-07-18 B Purchase
1.8
Denise Scots-Knight

Chief Executive Officer

Officer
2,000
2.55
£5,100 		2,000 2.55 £5,100
2019-07-19 2019-07-18 B Purchase
1.8
Denise Scots-Knight

Chief Executive Officer

Officer
8,000
0.45
£3,600 		8,000 0.45 £3,600
2019-07-19 2019-07-17 B Purchase
1.8
Denise Scots-Knight

Chief Executive Officer

Officer
2,000
2.59
£5,180 		2,000 2.59 £5,180
2019-07-19 2019-07-17 B Purchase
1.8
Denise Scots-Knight

Chief Executive Officer

Officer
2,000
0.45
£900 		2,000 0.45 £900
2019-05-23 2019-05-22 B Purchase John Richard

Head of Corporate Development

Officer
3,000
4.90
US$14,709 		3,000 4.90 US$14,709
2019-05-23 2019-05-21 B Purchase Peter Bains

Director

Executive Director
778
4.92
US$3,828 		778 4.92 US$3,828
2019-05-23 2019-05-21 B Purchase Peter Bains

Director

Executive Director
47,500
0.90
£42,750 		47,500 0.90 £42,750
Explore more

More insider trading research around Mereo BioPharma Group PLC

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America